Do you ever consider close clinical monitoring over antifibrotic therapy in patients ascribed an MDD diagnosis of IPF who have normal lung function and are asymptomatic?
Answer from: at Academic Institution
Idiopathic pulmonary fibrosis is by definition a progressive disease with high mortality, thus, clinical practice guidelines would recommend treatment at diagnosis. Based on US and UK epidemiologic studies, IPF has an average life expectancy of 3-4 years without antifibrotic treatment. Furthermore, ...
Sign in or Register to read more
Answer from: at Academic Institution
Yes, but not often. It always seems odd to me that patients and some providers want to wait until there's progression.I had a mentor who told me there were three certainties in life: "Death, taxes, and IPF progresses." Clearly meant for comedic effect, but it's pretty true. If a patient doesn't prog...